Home » Newsletters » BioWorld Science

BioWorld Science

May 26, 1998

View Archived Issues

Company Profile: Novalon

Organogenesis: Q1 1998 highlights

MCP-1 antagonists from Warner-Lambert that inhibit inflammatory cell recruitment

MGI Pharma updates shareholders at annual meeting

Long-term efficacy of lamivudine in hepatitis B; overview of antihepatitis research in U.S.

LeukoSite: Q1 1998 highlights

Cortex obtains additional patent rights for potential schizophrenia treatments

Nyotran demonstrates broad antifungal activity against multiple fungal species

Modified oligosaccharide cell adhesion inhibitors developed at Novartis

Glycine-site NMDA antagonists from Glaxo Wellcome

Profile of ACE inhibition and antihypertensive effects of zofenopril in volunteers and patients

Neurobiological Technologies receives patent allowance for its liquid form of Xerecept

Pivotal trials of Allovectin-7 begin in advanced metastatic melanoma

Yamanouchi and Glaxo Wellcome sign development agreement

Oral contraceptive approved for acne treatment in Canada

NeoTherapeutics' candidate compounds AIT-082 and AIT-034 presented at scientific meeting

Takeda establishes independent U.S. company, begins partnership with Lilly

Therapeutic effects of adenosine A2A blockade in Parkinson's disease and cerebral ischemia

Patent covering MEKK-related assays licensed to Cadus

Enhanced antitumor activity of methotrexate using MTX-HSA conjugate

Sepracor receives patent covering single isomer of the antihistamine cetirizine

Searle acquires Poli's Italian pharmaceutical line

Bio-Technology General and Serono announce copromotion agreement

NPS Pharmaceuticals: Q1 1998 highlights

Hyaluronate effective in preventing rejection in rat kidney allograft model

Effects of ACE inhibition and beta-adrenoceptor blockade on intimal hypertrophy in renal Tx

Bayer quinolone shows low potential for bacterial resistance and phototoxicity

Synsorb Biotech expands phase II trial of Synsorb Cd

Improved formulation of paclitaxel in development at P&U

Glaxo Wellcome's 3622W94: phase I trial results presented at ASCO

Pharma Mar's ET-743: phase I efficacy and pharmacokinetic data reported

Clinical efficacy of SB-209670 in hypertensive patients

First launch for Aggrastat, a new antiplatelet agent for acute coronary syndrome

Pharmos' neuroprotectant shows additional utility in IBD and anorexia

Human leukocyte elastase inhibitors in development at Sanofi